David Veale, R&D Associate at RB. BSc (Hons) in Chemistry from the University of Newcastle. David has worked for several years within RB across a range of R&D healthcare departments, and currently works in the Respiratory R&D team. David has experience in formulation and analysis of prescription, pharmacy and GSL medicines within the RB portfolio. His current role is innovation focussed and spans brands including Strepsils, Mucinex and Lemsip. Prior to RB, David had begun his industrial career in QC analysis of the nutritional content of food products.
Sore throat sprays provide targeted relief by delivering the active ingredient directly to the site of pain. Although there are several throat sprays available, they vary with respect to the spray pattern, thus affecting delivery of the active ingredient to the throat. The characteristics and performance of flurbiprofen 8.75 mg sore throat spray were compared with 12 competitor sprays. Parameters assessed include spray pattern, spray angle, droplet size, distribution, uniformity of dosage units and number of doses per bottle. Studies were conducted by an independent agency and tests were automated. The analysis showed that flurbiprofen 8.75 mg sore throat spray had the second tightest spray angle (51°), producing a more targeted dose than most competitors. Droplet size distribution studies showed flurbiprofen 8.75 mg sore throat spray had the second smallest droplet size and was therefore one of the more mist-like sprays, ensuring gentle delivery of the dose to the throat with negligible risk of aspiration into the lungs. Analysis of the spray pattern showed that the spray volume delivered, and diameter of the area covered, was uniform and consistent throughout the whole container life. Flurbiprofen 8.75 mg sore throat spray also consistently delivered an accurate dose each time. These results show that flurbiprofen 8.75 mg sore throat spray performed well overall, providing a consistent, gentle and accurate dose of medication throughout the whole container life.
Tina Kauss (PharmD at University of Bordeaux and Master 2 of Pharmaceutical technology and Biopharmacy at University Paris 11) completed her PhD in 2007 at Bordeaux’s University, followed by 3 years of postdoctoral studies in pharmaceutical development (pharmaceutical technology, biopharmacy and analytical chemistry). Since 2011 she is assistant professor of Pharmaceutical technology and Biopharmacy at the University of Bordeaux. She has published 16 papers in reputed journals of pharmaceutical development.
SEDDS (self emulsifying drug delivery system) are commonly used for absorption enhancement of poorly soluble active pharmaceutical ingredients (APIs). However, when generating in situ a nanoemulsion, beside common absorption via drug passive diffusion, additional mechanisms like lymphatic absorption of nanodrops can occur. The aim of our work was to evaluate whether a SEDDS formulation can improve the bioavailability of highly soluble, but weakly permeable drug (class III of Biopharmaceutical classification system, BCS). An additional challenge was to adapt the formulation to rectal route, where the quantity of physiological liquid for emulsion reconstitution is limited. Ceftriaxone was used as a model drug of BCS III API. Reportedly, ceftriaxone rectal absorption is very low, about 3% if not accompagnied by an absorption enhancer. From previous studies (Roche’s personal communication), sodium chenodeoxycholate was chosen as optimal absorption enhancer for all tested formulaitons. To define the formulation, a screening of oily vehicles, surfactants and co-surfactants was performed using ternary diagrams. The formulation was further optimized by 23 full factorial design. The impact of formulation on dissolution rate, size of droplets after reconstitution, time necessary for reconstitution were considered. In vivo bioavailability of the selected SEDDS formulation was further assessed in rabbits and compared with oily suspension and IV route.